40CDF034-0EBC-42A1-BBD8-492C1494086E
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 3.1865965834428382
- age_years
- 63
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.622
- MYC_TARGETS_V1+0.540
- ANGIOGENESIS+0.531
- G2M_CHECKPOINT+0.526
- DNA_REPAIR+0.520
- MYC_TARGETS_V2+0.482
- INTERFERON_GAMMA_RESPONSE+0.478
- INTERFERON_ALPHA_RESPONSE+0.455
- IL6_JAK_STAT3_SIGNALING+0.453
- NOTCH_SIGNALING+0.439
Top 10 suppressed
- KRAS_SIGNALING_DN-0.351
- SPERMATOGENESIS-0.193
- MYOGENESIS-0.120
- ESTROGEN_RESPONSE_EARLY-0.015
- HEDGEHOG_SIGNALING-0.011
- UV_RESPONSE_DN+0.014
- BILE_ACID_METABOLISM+0.017
- PANCREAS_BETA_CELLS+0.026
- ESTROGEN_RESPONSE_LATE+0.028
- HEME_METABOLISM+0.038
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.959 |
| 2 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.958 |
| 3 | 541FDA8B-9FAE-4346-A6FD-C56735C87920 | — | — | 0.957 |
| 4 | EC1C727A-1F71-4C09-B867-7F163424D463 | — | — | 0.955 |
| 5 | 30D8578D-0B48-4D03-9E39-6425494ECD5C | — | — | 0.954 |
| 6 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.950 |
| 7 | 8D986787-7BD1-4F66-837E-88CD2A4CEA68 | — | — | 0.950 |
| 8 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.948 |
| 9 | B27956E8-3374-4720-9F80-7CE6FE7C7690 | — | — | 0.947 |
| 10 | 8976C50F-B340-488D-B9C1-12CCAC780397 | — | — | 0.946 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.622 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.531 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.526 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.520 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.482 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.478 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.455 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.453 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.439 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.433 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.409 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.407 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.376 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.346 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.333 | Idelalisib | — uncovered |
| APOPTOSIS | 0.329 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.318 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.301 | Inavolisib | — uncovered |